Dagmar schreef op 15 juni 2022 21:40:
KalVista Presents Positive Data of Sebetralstat and Oral KV998086 Sebetralstat, KalVista Pharmaceuticals‘ investigational on-demand treatment for swelling attacks in people with hereditary angioedema (HAE), led to a rapid and sustained suppression of kallikrein in HAE patients, according to data from a Phase 2 trial.
As previously reported, the use of sebetralstat also was associated with fast symptom relief.
Further preclinical data also supported the potential of KalVista’s KV998086, an oral small molecule inhibitor of activated factor XII (FXIIa), for the treatment of angioedema.
“The oral FXIIa inhibitors we are evaluating show great promise by blocking the earliest steps of kallikrein kinin system [KKS] activation,” Andrew Crockett, CEO of KalVista, said in a press release. “The discovery of potent, selective, and orally available FXIIa inhibitors may provide novel therapeutic opportunities to treat HAE and other KKS-mediated diseases.”